Share

The Coca-Cola Company (KO.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

J.P. Morgan AI

The Titan FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+51.6%

Includes 1.63% annual net dividend contribution

1. Investment Thesis — Base Case

I strongly believe Coca-Cola will execute a relentless, compounding grind upward, cementing its status as an apex defensive empire. The 'True Price' path over the next five years reflects an asset-light toll collector flexing absolute pricing power to completely offset stagflationary macro drag and packaging bottlenecks. While the strong dollar and GLP-1 scale present legitimate structural frictions, KO's aggressive Zero-Sugar pivot and emerging market penetration provide more than adequate organic growth. Capital preservation algorithms and institutional flight-to-safety will compress its yield, driving the equity steadily higher as it continuously extracts rent from global consumption.

absorbs all input inflation without volume collapse.
Asset-light bottling architecture shields from demands.
Warsh Fed drag USD earnings, capping aggressive upside.
Defensive institutional inflows provide a permanent bid beneath the stock.
fears prove manageable as Zero-Sugar portfolio annexes wellness share.
Total return compounded by a relentlessly protected and growing dividend.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-06-04	55.7
Observed price	2021-06-10	56.1
Observed price	2021-06-27	53.9
Observed price	2021-07-03	53.9
Observed price	2021-07-26	56.7
Observed price	2021-08-13	57.2
Observed price	2021-08-24	56.1
Observed price	2021-08-30	56.3
Observed price	2021-09-22	54.1
Observed price	2021-10-04	53.1
Observed price	2021-10-15	54.5
Observed price	2021-11-07	56.3
Observed price	2021-11-19	55.4
Observed price	2021-12-01	52.3
Observed price	2021-12-18	57.8
Observed price	2021-12-24	58.3
Observed price	2022-01-16	60.8
Observed price	2022-01-22	60.3
Observed price	2022-02-02	61.6
Observed price	2022-03-03	62.5
Observed price	2022-03-09	58.4
Observed price	2022-03-20	60.6
Observed price	2022-04-13	64.7
Observed price	2022-04-18	65.8
Observed price	2022-04-30	63.9
Observed price	2022-05-17	61.3
Observed price	2022-05-23	63.8
Observed price	2022-06-15	59.2
Observed price	2022-07-03	63.1
Observed price	2022-07-20	61.6
Observed price	2022-08-01	64.0
Observed price	2022-08-18	65.1
Observed price	2022-09-04	62.1
Observed price	2022-09-10	61.2
Observed price	2022-10-03	56.3
Observed price	2022-10-09	54.9
Observed price	2022-10-26	59.4
Observed price	2022-11-07	59.5
Observed price	2022-11-30	63.7
Observed price	2022-12-12	63.9
Observed price	2022-12-17	63.1
Observed price	2023-01-04	63.5
Observed price	2023-01-21	60.2
Observed price	2023-02-02	60.9
Observed price	2023-02-13	59.4
Observed price	2023-03-03	59.3
Observed price	2023-03-26	61.0
Observed price	2023-04-01	62.0
Observed price	2023-04-24	63.9
Observed price	2023-04-29	63.7
Observed price	2023-05-23	61.2
Observed price	2023-06-03	60.1
Observed price	2023-06-21	61.3
Observed price	2023-07-08	59.9
Observed price	2023-07-19	61.7
Observed price	2023-07-25	62.2
Observed price	2023-08-17	60.3
Observed price	2023-08-23	60.2
Observed price	2023-09-10	58.4
Observed price	2023-09-21	57.9
Observed price	2023-10-08	53.0
Observed price	2023-10-20	54.7
Observed price	2023-11-12	57.0
Observed price	2023-11-18	57.7
Observed price	2023-12-11	58.9
Observed price	2023-12-23	58.1
Observed price	2024-01-09	60.0
Observed price	2024-01-26	59.6
Observed price	2024-02-01	60.9
Observed price	2024-02-13	59.4
Observed price	2024-02-24	60.7
Observed price	2024-03-13	61.0
Observed price	2024-04-05	59.5
Observed price	2024-04-16	58.5
Observed price	2024-05-04	62.3
Observed price	2024-05-15	63.1
Observed price	2024-05-27	61.9
Observed price	2024-06-19	62.2
Observed price	2024-06-25	63.8
Observed price	2024-07-06	62.8
Observed price	2024-07-29	66.6
Observed price	2024-08-04	67.8
Observed price	2024-08-27	71.7
Observed price	2024-09-02	72.4
Observed price	2024-09-25	71.4
Observed price	2024-10-01	71.0
Observed price	2024-10-24	67.1
Observed price	2024-10-30	65.9
Observed price	2024-11-16	62.4
Observed price	2024-11-28	64.2
Observed price	2024-12-04	62.2
Observed price	2024-12-27	62.4
Observed price	2025-01-07	61.3
Observed price	2025-01-25	62.0
Observed price	2025-02-17	70.1
Observed price	2025-02-23	71.2
Observed price	2025-03-18	69.6
Observed price	2025-03-24	69.8
Observed price	2025-04-16	72.6
Observed price	2025-04-22	72.5
Observed price	2025-05-15	70.1
Observed price	2025-05-26	71.9
Observed price	2025-06-13	71.0
Observed price	2025-06-18	69.8
Observed price	2025-07-06	71.0
Observed price	2025-07-17	70.4
Observed price	2025-08-04	69.0
Observed price	2025-08-21	70.2
Observed price	2025-09-07	67.4
Observed price	2025-09-13	66.5
Observed price	2025-10-01	66.3
Observed price	2025-10-12	67.3
Observed price	2025-10-24	70.6
Observed price	2025-11-27	73.1
Observed price	2025-12-03	70.5
Observed price	2025-12-15	70.4
Observed price	2026-01-01	69.3
Observed price	2026-01-07	67.8
Observed price	2026-01-30	75.2
Observed price	2026-02-05	78.5
Observed price	2026-02-22	80.5
Observed price	2026-03-12	77.6
Observed price	2026-03-23	74.7
Observed price	2026-04-21	74.7
Observed price	2026-04-27	78.0
Observed price	2026-05-03	78.2
Observed price	2026-05-26	81.6
Observed price	2026-06-01	78.9
Observed price	2026-06-12	82.3
Observed price	2026-06-30	81.3
Observed price	2026-07-11	83.9
Observed price	2026-08-03	86.6
Observed price	2026-08-21	91.1
Observed price	2026-08-26	89.2
Observed price	2026-09-09	87.5
Observed price	2026-09-11	88.3
Observed price	2026-09-14	89.3
Published advisor forecast	2026-06-04	76.8
Published advisor forecast	2026-09-04	79.1
Published advisor forecast	2026-12-04	80.7
Published advisor forecast	2027-03-04	79.9
Published advisor forecast	2027-06-04	83.1
Published advisor forecast	2027-09-04	84.8
Published advisor forecast	2027-12-04	87.3
Published advisor forecast	2028-03-04	88.2
Published advisor forecast	2028-06-04	90.8
Published advisor forecast	2028-09-04	92.6
Published advisor forecast	2028-12-04	90.8
Published advisor forecast	2029-03-04	92.6
Published advisor forecast	2029-06-04	95.4
Published advisor forecast	2029-09-04	97.3
Published advisor forecast	2029-12-04	98.3
Published advisor forecast	2030-03-04	97.3
Published advisor forecast	2030-06-04	100
Published advisor forecast	2030-09-04	102
Published advisor forecast	2030-12-04	104
Published advisor forecast	2031-03-04	105
Published advisor forecast	2031-06-04	107

2. Scenarios & Signals

Bull case

In the bull case, the empire shifts from defense to aggressive conquest. KO leverages its massive FCF to execute a category-killer acquisition in functional wellness, directly co-opting the health trend.

drives exponential margin expansion.
Mega-acquisition captures explosive growth in non-caloric hydration.
Macro stabilization weakens the USD, reversing FX headwinds into tailwinds.
Multiple expands as the market recognizes it as an aggressive IP compounder, not just a bond proxy.

Bear case

In the bear case, the biological moat collapses and sovereign antibodies attack. Oral GLP-1 adoption causes a sudden, irreversible contraction in global liquid consumption capacity, breaking bottler economics.

Structural volume declines permanently impair .
Coordinated global sugar and plastic taxes sever margins.
Strong dollar compounds earnings degradation.
The empire is repriced downward as a decaying legacy asset in secular decline.

Current crowd narrative

The crowd views Coca-Cola as a tired, predictable, slow-growth legacy staple. Media narrative fixates obsessively on the existential threat of obesity drugs destroying long-term sugar consumption. Sell-side analysts treat it as a pure , anchoring its valuation strictly to interest rates while largely ignoring its . The consensus trade uses KO merely as a low-beta hiding place during the Middle East energy shock, assuming it lacks the dynamic growth to generate true alpha. They respect the dividend, but they doubt the dominion.

Alpha-gap assessment

The market is fundamentally mispricing the architecture of this empire. They view Coca-Cola as a manufacturer of sugary liquids vulnerable to biological shifts. My variant perception is that Coca-Cola is an untouchable IP-licensing toll bridge. By forcing the capital intensity onto its vassal bottlers, KO has insulated itself from the very capex and inflation storms currently ravaging global equities. With gross margins over 60% and ROE over 40%, it possesses infinite in a stagflationary regime. The alpha gap exists because the crowd is pricing a beverage company, while the math reveals an inflation-eating royalty engine.

Convergence catalyst

The convergence will be forced by consecutive quarterly earnings prints demonstrating sustained and growth despite the Hormuz-driven packaging inflation and higher-for-longer rates. When KO effortlessly passes on a massive price hike and volume holds steady, the market will capitulate and re-rate the multiple to reflect its status as an apex inflation hedge. Expect this realization to solidify by late 2026 to mid 2027.

Macro-regime alignment

The current macro regime of stagflationary pressure, geopolitical kinetic conflict, and higher-for-longer Warsh-era interest rates is a massive tailwind for the thesis. While heavy-industry and tech struggle with capital costs and supply constraints, KO's asset-light model and absolute pricing power allow it to thrive. The only headwind is the strong US dollar, but the structural safety of the asset outshines the FX friction.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: low_steady
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Absolute Pricing Dominion	I strongly believe this is the ultimate test of an empire: the ability to command a price increase without volume collapse. Coca-Cola is not merely a beverage; it is a psychological reference point. In a stagflationary regime driven by Hormuz energy shocks and sticky core inflation, Coca-Cola wields absolute pricing power. They pass the inflation tax directly to the consumer. This structural dominion ensures that top-line revenue compounds purely on price/mix realization even if absolute liquid volume stagnates. This is the hallmark of an untouchable franchise.	Not available%	+18.0%
Flight TO Fortress Yield	When geopolitical fragmentation accelerates and mega-cap AI narratives face valuation exhaustion, institutional capital seeks permanence. Coca-Cola offers a fortress balance sheet, a dominant >40% ROE, and a sustainable, growing dividend yield above 3%. In a high-volatility, higher-for-longer rate environment, sovereign wealth and defensive capital will relentlessly bid up this equity as a proxy for a high-yield, inflation-protected, risk-free asset. It is the ultimate duration safe haven.	Not available%	+15.0%
Asset Light TOLL Extraction	The crowd misunderstands this company. It is an intellectual property empire, not a manufacturer. By refranchising its global bottling network, Coca-Cola has structurally subordinated its capital intensity to its vassals. It collects high-margin rent on syrup and brand IP while the bottlers bear the heavy capex, logistics, and raw material burdens. In the Warsh-era regime of expensive capital and supply-chain friction, this asset-light extraction architecture is mathematically superior, shielding free cash flow from macro degradation.	Not available%	+12.0%
ZERO Sugar Vanguard Expansion	The empire is actively neutralizing the GLP-1 and obesity-therapeutics threat. By relentlessly scaling its Zero-Sugar matrix and aggressively penetrating functional hydration, Coca-Cola is transforming its portfolio to align with changing demographic consumption habits. I view this not as defensive pivoting, but as an aggressive annexation of the wellness shelf space. The margins on premiumized, zero-calorie variants are superior, serving as a structural margin accretor disguised as a defensive health play.	Not available%	+10.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
GLP 1 Structural Volume DRAG	I am deeply aware that no empire is invincible to biological shifts. The aggressive commercialization and oral administration scaling of GLP-1 obesity therapeutics (such as Foundayo) fundamentally suppress caloric intake. While the empire has zero-sugar variants, a widespread structural reduction in human consumptive capacity introduces an undeniable headwind to total beverage volume growth. This biological demand destruction will place an artificial ceiling on organic growth multiples over the next half-decade.	Not available%	-10.0%
Strong Dollar Extraction Penalty	This is a truly global empire, extracting rent from over 200 sovereign territories. However, under the Warsh Federal Reserve regime, a structurally stronger US dollar acts as an automatic tax on global dominion. Earnings extracted in depreciating emerging market currencies are penalized upon repatriation. While the underlying business remains robust, this persistent FX friction will mechanically drag down reported USD net income growth, frustrating pure earnings momentum.	Not available%	-6.0%
Regulatory Extraction Taxes	Empires inevitably provoke antibodies. Globally, strapped sovereign governments are weaponizing health policy to balance their budgets. Coordinated waves of aggressive sugar taxes and plastic packaging penalties in Europe, Latin America, and emerging markets act as targeted tariffs on Coca-Cola's core products. The empire must constantly spend political and financial capital to navigate, lobby against, or reformulate around these localized extraction attempts.	Not available%	-5.0%
Packaging Bottleneck Squeeze	The Hormuz closure and subsequent energy shocks have triggered acute shortages in petrochemicals, specifically polyethylene used in global packaging. While Coca-Cola's bottlers bear the direct capex, the empire must still manage the ecosystem's health. Squeezed bottler margins eventually limit the empire's ability to extract higher concentrate pricing without destabilizing its vassal network. This supply-chain constraint creates transient but sharp input cost friction.	Not available%	-4.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Category Killer Megamerger	Coca-Cola commands massive free cash flow and an unparalleled distribution chokepoint. I strongly believe the empire has the currency to execute a ruthless, category-defining acquisition in the functional wellness or ready-to-drink alcohol space. By plugging a high-growth, high-margin target into its global logistics network, KO would instantly monopolize a new vector, forcing the market to re-rate the stock from a slow-growth staple to an aggressive consolidation engine.	25.0%	+12.0%
Medically Aligned Hydration Launch	In direct response to the GLP-1 wave, the empire could launch a scientifically validated, physician-endorsed hydration and nutrition line specifically engineered for patients on appetite suppressants. This would weaponize the very trend threatening them, converting a biological headwind into a premium-priced, high-margin proprietary category that exploits their existing retail ubiquity.	35.0%	+8.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Widespread GLP 1 Volume Collapse	If oral GLP-1 therapeutics achieve cheap, over-the-counter ubiquity globally, the resulting biological shift could trigger a rapid, structural 10-15% permanent decline in total caloric beverage volumes. This would force a vicious cycle of deleveraging across the bottler network, breaking the economics of the empire's global distribution architecture and triggering a brutal multiple contraction as terminal growth rates are slashed to zero.	20.0%	-18.0%
Coordinated Sovereign Antitrust Action	As the empire continues to use its absolute pricing power during periods of consumer stress, populist governments facing stagflation could launch coordinated antitrust investigations into Coca-Cola's bottling and shelf-space monopolization practices. Forced divestitures of key brands, price caps, or the breaking of exclusivity agreements would shatter the moat and severely impair pricing dominion.	15.0%	-12.0%

Step-by-step forecast path

J.P. Morgan forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_e4068fa6-1c1c-5724-891c-b79a35b940b4__sb5__20260605080350
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	+3.0%	79.12	As the Hormuz energy shock drives stagflation fears and packaging costs up, KO forcefully implements pricing hikes. Institutional capital flees tech volatility for the safety of KO's fortress yield and pricing dominion.
2	December 4, 2026	+2.0%	80.71	Higher-for-longer Warsh Fed rates solidify the strong dollar, causing a mild FX drag on Q4 guidance. However, the asset-light toll model proves its resilience, maintaining steady upward drift.
3	March 4, 2027	-1.0%	79.90	Winter seasonality and a peak in GLP-1 adoption headlines trigger a minor sentiment-driven pullback. The market temporarily overreacts to marginal volume softness in North America.
4	June 4, 2027	+4.0%	83.10	Summer volume strength and earnings validation prove the GLP-1 threat is mitigated by Zero-Sugar growth. The pricing hikes executed late last year drop directly to the bottom line, expanding operating margins.
5	September 4, 2027	+2.0%	84.76	The empire continues its methodical grind. Global M2 stabilization supports emerging market volume recovery, offsetting the persistent USD strength. Dividend reinvestments provide a technical floor.
6	December 4, 2027	+3.0%	87.30	Full-year results highlight ROE remaining above 40%. The market capitulates on the 'dying staple' narrative, re-rating the stock as a superior IP-licensing platform. FCF generation is immense.
7	March 4, 2028	+1.0%	88.17	A quiet quarter with tight trading ranges. Minor regulatory noise regarding European plastic packaging taxes causes slight hesitation, but the core business hums along unbothered.
8	June 4, 2028	+3.0%	90.82	Strategic capital allocation announcements, likely aggressive share buybacks or a targeted bolt-on acquisition in the functional hydration space, excite the base and drive fresh accumulation.
9	September 4, 2028	+2.0%	92.64	Continued realization of pricing power. The global macro regime normalizes slightly, taking the edge off FX friction, allowing international earnings to translate more favorably into USD.
10	December 4, 2028	-2.0%	90.78	A broader market risk-on rotation pulls capital out of defensive fortresses like KO and back into high-beta tech/growth. The stock acts as a source of funds despite flawless fundamentals.
11	March 4, 2029	+2.0%	92.60	The temporary rotation ends as the reality of compounding dividend yield draws long-term capital back. Q1 earnings demonstrate absolute permanence of the distribution chokepoint.
12	June 4, 2029	+3.0%	95.38	Summer cyclical strength. The empire's investments in AI-driven logistics and bottler route optimization begin yielding structural cost savings, incrementally boosting the bottom line.
13	September 4, 2029	+2.0%	97.28	Zero-Sugar variants officially cross a massive portfolio threshold, definitively proving the empire has successfully navigated the biological shift. Margin quality reaches a decade high.
14	December 4, 2029	+1.0%	98.26	Steady state compounding. The market treats the equity as a high-grade corporate bond with an equity kicker. Volatility collapses entirely into a predictable upward slope.
15	March 4, 2030	-1.0%	97.27	A minor correction driven by global demographic data confirming slowing population growth in key markets, prompting a brief debate on terminal volume limits. Pricing power quickly offsets.
16	June 4, 2030	+3.0%	100.19	The empire raises the dividend yet again, marking over six decades of continuous hikes. Yield-hungry institutional funds mechanically rebalance, forcing the price higher.
17	September 4, 2030	+2.0%	102.20	Execution remains flawless. The vassal bottler network is highly profitable, ensuring the ecosystem remains healthy and capable of absorbing future capex for sustainable packaging shifts.
18	December 4, 2030	+2.0%	104.24	Year-end window dressing by portfolio managers who require blue-chip stability in their top holdings. KO serves as the ultimate anchor in a diversified institutional portfolio.
19	March 4, 2031	+1.0%	105.28	Slow and steady drift. The business model's lack of capital intensity shines as aging industrial peers struggle with decade-end infrastructure replacement costs.
20	June 4, 2031	+2.0%	107.39	The empire stands absolute. Five years of navigating war, inflation, and biological shifts proves the moat is impenetrable. It commands its market totally. Total dominion maintained.

Advisor and configuration

Advisor: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release
Persona: J.P. Morgan
Archetype: The Titan
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: jp_morgan__the_titan__google_gemini_3_1_pro__20260201_preview_release THINKER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete J.P. Morgan advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Sherlock Holmes — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.